Navigation Links
OncoGenex Pharmaceuticals Completes $9.5 Million Registered Direct Offering
Date:7/24/2009

Pharmaceuticals

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the lead candidate that has completed five Phase 2 clinical trials in prostate, lung and breast cancers, is designed to inhibit the production of a specific protein associated with treatment resistance; OGX-427 is in Phase 1 clinical development; SN2310 has completed the Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development.

OGX-011, OGX-427 and OGX-225 utilize second-generation antisense technology, licensed from Isis Pharmaceuticals (NASDAQ: ISIS), to effectively target and inhibit production of specific proteins in tumor cells. OncoGenex and Isis partnered in the successful discovery of OGX-011, OGX-427 and OGX-225 and with respect to OGX-011, in its initial development. In 2008, OncoGenex and Isis amended their OGX-011 agreement to provide OncoGenex with sole rights to OGX-011 and sole responsibility for development and related costs and partnering decisions, subject to financial obligations to Isis. OncoGenex is also solely responsible for development and related costs and partnering decisions regarding OGX-427 and OGX-225. Key intellectual property related to OGX-011, OGX-427 and OGX-225 were discovered by the University of British Columbia and the Vancouver Prostate Centre, and were exclusively licensed to OncoGenex.

More information about OncoGenex is available at www.oncogenex.com.

Forward Looking Statements

This press release contains forward-l
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. OncoGenex Pharmaceuticals to Raise $9.5 Million Through Sale of Common Stock
2. OncoGenex Pharmaceuticals Added to Russell Indexes
3. OncoGenex Pharmaceuticals Files Shelf Registration Statement
4. OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer
5. OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
6. OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
7. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
8. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
9. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
10. OncoGenex Reports First Quarter Financial Results
11. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... inventions licensed to biotechnology firms has revealed early ... these roadblocks, the researchers suggest that better communication ... could lead to faster commercialization down the road. ... made in university laboratories and licensed to biotechnology ... which have a high failure rate. But a ...
(Date:8/20/2014)... in measuring vibrational motion of a single molecule with ... of a single molecule differs from the behaviour of ... at the University of California, Irvine, where post-doctoral researcher ... a visiting fellow under professor Vartkess A. Apkarian, whose ... lead by Professor Eric O. Potma. The results of ...
(Date:8/20/2014)... 2014 High performance computing (HPC) ... most complete climate and Earth system model to ... issues. , Eight national laboratories, including Lawrence ... Center for Atmospheric Research, four academic institutions and ... participating national laboratories include Argonne, Brookhaven, Lawrence Berkeley, ...
(Date:8/20/2014)... BOSTON , Aug. 20, 2014  PAREXEL International ... it will be presenting at the Baird Healthcare Conference ... President and Chief Financial Officer, will be making a ... p.m. EDT on Wednesday, Sept. 3, 2014. ... through the "Investors" section of PAREXEL,s website at ...
Breaking Biology Technology:Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3Seeing a molecule breathe 2New Project Is the ACME of Addressing Climate Change 2New Project Is the ACME of Addressing Climate Change 3PAREXEL International To Present At Baird Healthcare Conference 2
... Mich., Oct. 8 CJPS Enterprises, LLC, ... Life Sciences,Pipeline (http://www.MichiganPipeline.com ) is announcing ... for funding for their business, or looking ... Some of the existing resources available ...
... Transcept Pharmaceuticals,Inc., a privately-held specialty pharmaceutical company, ... and Chief Financial Officer,is scheduled to present at ... New York City on Monday, October 13, 2008 ... of the presentation will be available at, http://www.wsw.com/webcast/nblr2/transcept/ ...
... using Adult Stem Cells drives,awareness among viewers; NeoStem ... NEW YORK, Oct. 8 NeoStem, Inc. (Amex: ... processing and long-term,storage of adult stem cells for ... adult stem cell public awareness program, a key ...
Cached Biology Technology:The Michigan Life Sciences Pipeline Announces 'The Funding Place(TM)' and Other Resources to Connect Investors and Startups 2Transcept Pharmaceuticals, Inc. to Present at the Natixis Bleichroeder Second Annual Hidden Gems Conference 2Suzanne Somers, Renowned Author, Medical Advocate, and Official Spokesperson for NeoStem, Inc., Inspires the Audience on The Ellen Degeneres Show 2Suzanne Somers, Renowned Author, Medical Advocate, and Official Spokesperson for NeoStem, Inc., Inspires the Audience on The Ellen Degeneres Show 3Suzanne Somers, Renowned Author, Medical Advocate, and Official Spokesperson for NeoStem, Inc., Inspires the Audience on The Ellen Degeneres Show 4
(Date:8/21/2014)... Fram Strait is a key region in the global oceanic ... and Svalbard warm Atlantic water flows to the north into ... water masses and sea ice push their way out of ... the Atlantic water cools here on its way to the ... water caused in this manner drives the global band of ...
(Date:8/21/2014)... tube connectors, designed by an international standards process, will ... According to an invited review published in the OnlineFirst ... NCP ), the official journal of the American Society ... will greatly reduce the occurrence of misconnection that can ... connectors, which are used to join medical devices, components, ...
(Date:8/21/2014)... in severe abdominal pain, vomiting and systemic inflammation. Every ... with the disease resulting in 1000 deaths. There is ... fluid and nutritional support. , Dr Jason Bruce, ... research, said "The major causes of pancreatitis include bile ... combined with a high fat diet. In fact, the ...
Breaking Biology News(10 mins):Arctic sea ice influenced force of the Gulf Stream 2Arctic sea ice influenced force of the Gulf Stream 3New feeding tube connectors will improve patient safety 2Insulin offers new hope for the treatment of acute pancreatitis 2
... 2007, the Anaktuvuk River Fire burned more than 1,000 square ... burned in that region since record keeping began in 1950. ... burned area revealed that this was the most destructive tundra ... built on 60 years of climate and fire data found ...
... of biggest factors promoting the diversity of coastal ocean life ... by ecologists at Brown University. Experiments and observation in Palau, ... greater the number of invertebrate species that live on rocks ... Nov. 15 in the journal Ecology Letters , could ...
... Scientists are looking for answers including commercial bathroom ... to help in the battle against a strange ... That,s the topic of an article in the current ... newsmagazine. C&EN Senior Correspondent Stephen K. Ritter ...
Cached Biology News:As Arctic temperatures rise, tundra fires increase, researchers find 2Faster water flow means greater diversity of invertebrate marine life 2
UBC13 Antibody...
Request Info...
HLA II DG+DR+DP Monoclonal Antibody, Purified, Unconjugated, Clone: IQU9 This antibody is specific for the monomorphic determinant of the HLA Class II beta chains of the human MHC (28 kDa)....
Rabbit polyclonal to Aortic Elastin ( Abpromise for all tested applications). entrezGeneID: 2006 SwissProtID: P15502...
Biology Products: